Ladies and gentlemen, thank you for standing by, and welcome to the MEDNAX Third Quarter Earnings Call. [Operator Instructions] And also, as a reminder, today's conference call is being recorded. I would now like to turn the conference over to your host, Mr. David Parker, Vice President of Investor Relations. Please go ahead.

Thank you, Anna, and good morning and welcome to our 2012 third quarter earnings conference call. Certain statements and information during this conference call may be deemed to be forward-looking statements within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on assumptions and assessments made by MEDNAX's management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements made during this call are made as of today, and MEDNAX undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the company's most recent annual report on Form 10-K and its quarterly reports on Form 10-Q, including the sections entitled Risk Factors. With that, I would now like to turn the call over to our Chief Executive Officer, Dr. Roger Medel.

Thank you, David. Good morning, everyone, and thanks for joining the call today to discuss our 2012 third quarter results. As we reported in our release earlier this morning, we achieved strong earnings results for the third quarter, results we believe underscore our continuing ability to effectively grow through the significant contributions we're generating from our operations as well as from our ongoing physician practice acquisition program. I believe that our quarterly results also represent many of the effective long-term investment merits that come with the MEDNAX model, including clear and well-defined growth opportunities and industry-leading position in the market, attractive returns, a strong balance sheet and superior free cash flow generation. Our revenue growth for the third quarter increased by 16.1%, with growth attributable to contributions from recently acquired practices at over 13% and the remainder coming from our same unit results. This revenue growth exemplifies what the future of MEDNAX looks like. Our path forward [indiscernible] developing the MEDNAX national group practice model, one that we have been deliberately building upon and methodically fine-tuning for over 3 decades now. Based upon our successful track record within the pediatrics platform, our significant and proven infrastructure to support our practices and a focus on quality measures that is unparalleled, we are now effectively replicating and enhancing our core competency of a national medical group practice in the anesthesiology specialty. To highlight the importance of anesthesiology as a long-term growth platform for MEDNAX, in the third quarter, we held our first ever American Anesthesiology Analyst Day. The goal of this Analyst Day was to provide a deeper look at our anesthesia division and outline our group [indiscernible] for growth in anesthesiology. We covered several initiatives associated with our development of industry-leading anesthesia operations and, through these efforts, how we are effectively…

Thanks, Roger. Good morning, and thanks for joining our call. As Roger mentioned, we are very pleased with our results for the third quarter and the first 9 months of 2012, highlighted by our strong revenue growth and by our earnings results exceeding our guidance. Net patient service revenue for the 3 months ended September 30, 2012, increased by 16.1% to $273.1 million from $407.7 million for the comparable prior-year period. Our revenue growth attributable to contributions from recently acquired practices was 13.6%, while same-unit revenue grew by 2.5% for the 2012 third quarter when compared to the prior-year period. Of this 2.5% same-unit growth, revenue attributable to volume grew by 1.9%, while net reimbursement-related factors grew by 0.6%. Same unit growth attributable to patient volume includes growth in our hospital-based neonatal and other pediatric physician services, primarily newborn nursery services, as well as anesthesia services, partially offset by declines in our office-based pediatric cardiology and maternal-fetal services. For the 2012 third quarter, same-unit neonatal intensive care unit patient days increased by 3.7% when compared to the prior year period, while the number of births at our hospital, also same-unit, was slightly higher. Our same-unit revenue growth from net reimbursement-related factors was principally due to continued modest improvements in reimbursements received from third-party commercial payors as a result of the company's ongoing contract renewal processes, the flow-through of revenue from moderate price increases and an increase in the administrative fees received from our hospital partners due to the expansion of our services as a result of internal growth initiatives, partially offset by a shift in payor mix to government payors from commercial payors year-over-year. The percentage of services reimbursed under government programs increased by approximately 80 basis points during the 2012 third quarter compared to the prior year. Our profit…

Thank you, Vivian. Operator, let's go ahead and open up the call for questions, please.

[Operator Instructions] We'll go with Ryan Daniels from William Blair. Ryan Daniels - William Blair & Company L.L.C., Research Division: Roger, one for you on the M&A pipeline. Certainly, it sounds like from your commentary that it's a pretty good pipeline. And I'm curious if -- when you or your teams are out in the field if you noticed a sense of urgency from some of the physicians or larger groups in regards to the potential tax law changes. And if so, do you think that could bring the deals closer to a 2012 time frame versus spilling out into 2013 not knowing what the tax situation might be?

Definitely, we're not at a stage today where we can promise anyone that we will get anything closed before the end of the year. So the deals that we have that are in the pipeline that we plan on closing before the end of the year are already set. Any new groups that we're talking to and a number of other groups that we have spoken already know that we're not going to get those deals closed before the end of the year. So our goal is to get a couple of more deals done here before the end of the year, and the remainder of the deals will get done in 2013. Ryan Daniels - William Blair & Company L.L.C., Research Division: Okay, perfect. And then just as a follow-up a little bit about a different topic, but I noticed that some of the high-tech stimulus, the Stage 2 meaningful use regulations, that they clarified that the physicians who work in a hospital but actually use a separate system from that hospital's may be able to qualify. So I'm curious if you've done any works thinking about if Baby Steps, which I know is certified, can potentially qualify and, if so, what that might mean for you as you pursue those stimulus dollars.

Yes, we do. And we have seen that, obviously, and are very interested in it. And we do believe that since Baby Steps is certified, that we would qualify. There are some work that needs to be done in addition to what we've already done in order for Baby Steps to qualify. So we're not there yet. We need to work on some computerized order entry and other things that Baby Steps does not provide at this point in time. Ryan Daniels - William Blair & Company L.L.C., Research Division: Do you anticipate adding those functions and then trying to attach for meaningful use?

We're evaluating what that would mean, how much work that would take and whether, in fact, we would be able to add that to our existing program. I don't know at this point in time. We are meeting on it and we are evaluating it. But at this point in time, I'm not sure whether we'll get there.

We'll go to the line of Kevin Ellich, Piper Jaffray.

I guess, Roger, first off, could you give us any color? What are you guys hearing out of Washington in terms of the final Medicaid to Medicare rate parity? Any idea when that's going to come out? Or have you heard anything about what the final rule might entail?

I don't know any more than you do. I think that it's in the law, and they're saying that it is going to happen. We don't have anything like that in our numbers, so we're cautiously optimistic. But I don't know anymore. I'm sure -- Vivian, do you want to add...

Yes, Kevin, as you know, we kind of probably are hearing the same things you guys are, which is last week and after elections, I mean, all of these things that frankly have been the same that we've been talking about. So we have no reason to believe, other than just the whole thing getting repealed, that there is anything different from what we've been saying over the last few months. As you guys know, I've been cautious about it. And even for the first quarter, I think we need to be cautious because when the bill hopefully does pass, they'll -- then we will be able to start having conversations with the state Medicaid agencies and figuring out from a practical perspective how this is going to be implemented and when we can start seeing the dollars. And so I'm going to caution everybody on this call as it relates to first quarter because here we are at November 1 and we haven't seen the rule passed yet. So there's a lot of practicalities to it. Again, from a conceptual point of view, there's no question that we believe like we have no further intelligence that there's anything holding it up. So we really don't know.

Okay. And then second question. Looking at the deals you've done and the contribution that we saw this quarter and, obviously, mostly the same benefit in Q4, it kind of looks like your guidance might be conservative. We saw good G&A leverage this quarter. Are there any significant cost items that we're looking at next in Q4 maybe, like early buying of supplies or anything that we should be thinking about, Vivian?

No. What it is, Kevin, though, is the timing of the deals. Because as Roger said, we are looking to close several deals here before year end, but we're already 1 month into the fourth quarter. And so the timing of the closing of the deals, as I've said before to you guys, does impact the contribution. So I don't really think that it's necessarily conservative. It's more about when we estimate our timing of the closing of the deals there.

Our next question comes from Brooks O'Neil from Dougherty & Company. Brooks G. O'Neil - Dougherty & Company LLC, Research Division: I'm curious. We hear some talk about soft hospital volumes. Obviously, we didn't really expect that to impact the neonatal business, but I'm curious if you're seeing that across your covered hospitals. And if so, what impact is it having on the business?

We're not seeing what's been reported. We -- our hospitals, as we've talked about in the past, just have -- tend to attract more births because they have NICUs. And so while the volume is not back to what it was 4 years ago, we certainly haven't seen the decrease in volume that we've seen in the [ph] hospitals. Brooks G. O'Neil - Dougherty & Company LLC, Research Division: And is the same thing true, Roger, in the anesthesia business?

Yes. Brooks G. O'Neil - Dougherty & Company LLC, Research Division: Good. And then I was just curious. Obviously, there's one publicly traded emergency management company and one that was public but now it's private. We've gotten some sense that they have interest in the anesthesia. Obviously, they come at it more from a hospital contracting perspective. You guys come at it from a physician perspective. Can you just talk about that difference and what it means to you? What you think it might mean to the groups that are attracted to become part of MEDNAX?

Well, most groups we talk to don't want to be hospital employed. They -- so we haven't -- I'll tell you, we haven't lost any groups that we're interested in to an offer that's been made by the hospital. Often, we will respect the hospital and wait until the negotiations with their group have -- are done, and then we will come in and offer to negotiate with the group. But I'll say that every single time where we've been in a situation where a hospital may have been looking to acquire their group of anesthesiologists, it just hasn't happened. So I think it's -- as we've talked about for years, I think you're joining a group of your own peers where your interests are always going to be 100% aligned, where there's never going to be -- if you're working for a hospital or a university or something, at some point, the interests are not exactly 100% aligned. And so the big advantage here is just joining people that are on your side and that always are going to have the same interests as you have.

And our next question comes from Ralph Giacobbe with Credit Suisse. Ralph Giacobbe - Crédit Suisse AG, Research Division: So you saw a nice sequential jump in the margins, still down a little bit year-over-year. I guess when do you think you'd see that stabilize sort of from a year-over-year basis? And I guess as we start thinking about 2013, should we think about it as kind of continued top line strength as you make the deals with some margin pressure? Or do you think we can see it flat or even expand?

It's Vivian. So yes, I mean, as I've said to you guys before, I mean, we're happy with how it ended up this quarter. The variability is going to be based on the composition of the deals that we get into -- from the anesthesia perspective, as you know, there's variability, and even in our own core deals depending on whether it's a hospital based or office based -- as well as really what's happening with same unit. And so this year, we believe we fared quite well considering that we have seen -- as you guys know, for the first 3 quarters, we've seen increases in the P mix and we've still been able to offset that on the pricing side as well as on the volume side. So I think that there'll be some slight variability there. And so that will continue and it's hard for us to estimate that. On the operating income line, we will expect to get continued positive momentum there as we effectively integrate these deals. Obviously, at some point, we are making investments, specifically in anesthesia, to expand the infrastructure, but that will be a step function. And so overall, we've been pretty happy with the margin, where it's at. Ralph Giacobbe - Crédit Suisse AG, Research Division: And then I may have missed this, but did you give where you are in terms of the acquisitions relative to that kind of $300 million target that you had out there?

Well, we didn't, but I can give you the number because it'll be disclosed here in our 10-Q once we file it. So it's -- we're at about $206 million year-to-date. Ralph Giacobbe - Crédit Suisse AG, Research Division: $206 million?

Yes. Ralph Giacobbe - Crédit Suisse AG, Research Division: Any expectation of $300 million still stands?

Yes. Ralph Giacobbe - Crédit Suisse AG, Research Division: Okay. And then last one, if I could squeeze one in. In the release, you talked a little bit about declines in office-based pediatric cardiology and maternal-fetal services. So anymore just color there specifically?

No, I think the -- I mean, I think we've seen that some of our office-based practices, particularly in specific regions of the country, are seeing a decrease in their patient encounters. We also have seen a decrease in reimbursements to our pediatric cardiology practices based on the fact that their reimbursement for some of their cardiograms, sonograms, echocardiograms have decreased. So I think that, that's really what makes that up.

And our next question comes from Kevin Fischbeck with Bank of America.

This is actually Joanna Gajuk today in for Kevin. I have a question on the commentary in the press release and, I guess, on also from Gian [ph] on the call in terms of the drivers for price, increase in the average pricing. I noticed that this is the first time that these -- I mean, I haven't -- I don't remember seeing it, but the statement about the flow-through of revenue from modest price increases, so is there anything in particular there that you can highlight?

No. Typically, we look at our pricing every year. And so really, it -- every year, it continues to be there. We mention it depending on really, in any given quarter, as I think I've mentioned to most of you, what the drivers are, whether it's more dollars or less dollars in this quarter, specifically because we did have a P mix shift. That was highlighted as dollars. But theoretically, we'll have that in any given quarter because every year, we look at our price increases. So it's really what's more affected in this quarter because of the other metrics that drive the net pricing.

And also on the payor mix shift, in the release you said there was 80-basis-points shift towards the government reimbursement year-over-year. But what was that sequentially, the change?

Yes, it was sequential as well as year-over-year.

So sequentially, it was also down, or rather moved towards government payors by 80 basis points?

No, it was slightly higher than that, about 100.

Okay. So 80 bps year-over-year and maybe more than 100 sequentially?

Yes, 100 sequentially. Yes. By the way, just one other thing on that P mix, as you guys probably -- for those of you that know MEDNAX for a while, typically we do see there is some seasonality to it. And typically, from the second to the third quarter, we do see a shift towards government. We don't really know why, but historically that's been the case.

And our next question comes from Rob Mains with Stifel, Nicolaus. Robert M. Mains - Stifel, Nicolaus & Co., Inc., Research Division: Vivian, I want to follow up on your comments about the G&A leverage that you saw in the quarter. When you look out at anesthesiology, you mentioned that G&A could be kind of a step function as you make investments in the infrastructure. That kind of imply that we -- and I know that this isn't something you're necessarily going to see in the fourth quarter. But going forward, we could see kind of G&A step up, and that would be followed by cost improvements elsewhere on the income statement?

Well, I mean, as you know, MEDNAX is an operating company. And as some of you have written in your reports, we're always looking to manage cost. I mean, I do think that in anesthesia, I said that because I want to set the stage for that, because I think we have had here pretty good, positive momentum on that line. As you know, we look to expand this division. I do think at some point, we will have -- and we've had it this year, too. We've had some expansion there, so we're always looking at that. So I can't tell you specifically, Rob, that it's going to be one line item or another. But definitely, we're always looking at that to see what benefits we can have as we continue to grow. Robert M. Mains - Stifel, Nicolaus & Co., Inc., Research Division: Okay. And my second question was, you mentioned the seasonality that MEDNAX typically encounters. In terms of kind of the revenue seasonality, typically, I think third quarter tends to be your biggest one for births. Should we expect the kind of earnings pattern, other than what goes on in the first quarter with payroll taxes and bonuses and whatnot, to shift at all due to the increased concentration in anesthesiology?

No, we haven't seen that so far yet. I mean, our -- as you can see from our fourth quarter guidance, it's relatively in line with third quarter and that so far, we haven't seen that change other than what you mentioned, Rob, in the first quarter.

And our next question comes from Darren Lehrich from Deutsche Bank.

This is Dana Vartabedian in for Darren. I just wanted to get an update on length of stay in the quarter. And I guess any trends you've seen or expect with length of stay?

Yes, length of stay is up just very, very slightly. Do you have a number there 0.1 or something?

Yes, it's very moderate. Yes.

0.1, Dana. It's basically flat.

And our next question is from Kevin Ellich with Piper Jaffray.

I just had 2 quick follow-ups. First, going back to the pricing, what do you guys usually see from managed care rate increases? It seems like you've always built in annual escalators into some of the contracts. And are you still seeing slight increases?

Yes, we are, Kevin. I think we've talked about that here. I mean, we haven't seen -- I mean, the environment is challenging, as always. But -- and we're still seeing our escalators, and we're definitely still doing our strategy of, as you guys know, have multiyear contracts. And so we haven't really seen that materially change.

Sure. And so safe to say, Vivian, that you're not seeing any increased pressure from the managed care companies?

Well, I didn't say that. I said the environment is challenging, but I think we do a pretty good job at that, and we have managed care professionals in each one of our regions and it's one of the core competencies that the company has. But the environment out there is challenging, but we're certainly making it.

Got it. And then the other thing, it seems like you've talked about administrative fees that you collect from hospitals. How big are the fees? Or what percent of your revenues? Has it become material yet?

No, I mean, total -- I mean, as I said, total -- that total line on the net revenue, we typically don't break it up. It's just that -- to let everybody know it's been in the 6% range, on total consolidated revenue. And so it'll be slightly up this year about 60 basis points or so, but it's not really material in the big scheme of things. But it is a contributing factor on that net pricing line. And so that's why we've highlighted it for the last 3 quarters or so.

Great. And can you remind me? Does that come from the newborn business, the Pediatrix business? Or more from anesthesia or both?

From both. Because right, well, a lot of the increases that we're seeing there is because the dynamics of the hospital are changing, and so we have had -- we partnered with them to do several hospitalist programs. And typically, those programs do require a subsidy.

Our next question comes from Nicholas Jansen with Raymond James. Nicholas Jansen - Raymond James & Associates, Inc., Research Division: On the anesthesia front, you're hearing a lot of the hospitals seeing surgery shift from inpatient to outpatient. And I was just wondering, is there any reimbursement dynamics that are different for the anesthesiologists when you do an inpatient procedure relative to an outpatient procedure?

No, the billing is the same independently of where the services are being provided. Nicholas Jansen - Raymond James & Associates, Inc., Research Division: Okay, that's helpful. And then lastly, on the commentary surrounding the comp for [ph] -- was $300 million of spend for 2012. I think in the beginning of the year, it was tilted towards $200 million of anesthesia and $100 million of core. But obviously, the core has been a little bit slower relative to initial expectations, at least from our end. Are you still comfortable with that mix? Or is it perhaps going to be tilted a little bit more towards anesthesia relative to your prior views?

We have -- we still have a couple of things in our Pediatrix division pipeline that we hope to get done before the end of the year. So we're still hopeful that, that'll happen. But if not, we'll more than make up for it by our anesthesiology acquisitions. Nicholas Jansen - Raymond James & Associates, Inc., Research Division: That's great color. And then -- and just lastly, thinking about next year, I know you guys don't want to put out any kind of comments surrounding guidance. But $300 million is -- considering your strong cash flow and all the acquired acquisitions come with more cash flow, what are your thoughts surrounding the ability to replicate $200 million to $300 million each year in annual spend given what the current environment looks like today?

Well, we like our -- I'm just going to say this. We like our pipeline very, very much. We're very, very confident in our ability to continue to do deals. And I will be disappointed if we don't do more deals next year and spend more money next year that we're spending this year. By the end -- by next quarter, we'll give you a more definite answer, but I'll be very disappointed if we don't do more deals next year than we've done this year.

And our last and final question will come from Matt Weight from Company Feltl (sic) [Feltl and Company].

Just a question. Seeing the NICU patient days obviously was quite strong, up 3.7% this quarter, was there any -- one, was there any regions that stood out for a particular strength? And then also, typically, there's a tighter relationship with that growth percent and your overall same-unit patient volume growth. In this quarter, they diverged quite a bit, and I understand that the pediatric cardiology was down. But am I thinking about it wrong? It would seem that the other areas, maybe anesthesia, the volume also was quite low during the quarter as well.

It's Vivian. So yes, I mean, one of the things I've been trying to tell everybody is that years ago, we talked about NICU as it related to same units. So now exactly, there's -- as anesthesia grows and the other specialty grows, too, that's all a contributing factor. So that does bring home the point that you're saying. However, the volumes were positive for anesthesia. And really, what we said is exactly what it is, is it's -- year-to-date, we're still favorable in anesthesia for sure, and maternal-fetal services are also favorable year-to-date. They were more negative in the quarter. But certainly, on a year-to-date, the only one that is -- continues to be negative in the quarter as well as year-to-date is pediatric cardiology. For what Roger mentioned, we are seeing some pressures there on the pricing side as well as on the volume side. But we're happy with the volumes in the other specialties and certainly in anesthesia for the quarter as well as for the year.

One of the things that we saw this quarter was sort of that variability in volume starting to decrease across the different regions. And to answer your question, we did see some nice growth out of our Texas region in same-store volume for NICU patients.

And then just last question quickly. Obviously, you had some nice G&A leverage. It was flat actually sequentially, dollar-wise. Is -- was there anything that was excluded that you pushed off? Or are these levels really sustainable kind of going forward?

Well, like I was mentioning to Rob, I do think that we're a pretty good operating company, and that's reflected in that line item on G&A. And we'll -- we're going to continue to manage that the best we can. And there will be some steps in it as we grow that platform given Roger's comments on the acquisitions, right? But basically, I think we've always managed that pretty well, and I do see us doing that going forward.

And I will now turn the conference back over to your host for any closing remarks.

Thank you, operator. If there aren't any more questions, I'll just thank everyone for being on the call this morning, and we look forward to speaking with you next quarter.

And ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T Executive TeleConference Inc. You may now disconnect.